Insider Selling: Eleven Biotherapeutics major shareholder Sells 2,600 Shares of Stock (EBIO)
Eleven Biotherapeutics (NASDAQ:EBIO) major shareholder Jafco Super V3 Investment Limi sold 2,600 shares of the company’s stock on the open market in a transaction that occurred on Monday, August 18th. The stock was sold at an average price of $11.81, for a total value of $30,706.00. Following the completion of the transaction, the insider now directly owns 2,122,691 shares of the company’s stock, valued at approximately $25,068,981. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Large shareholders that own more than 10% of a company’s stock are required to disclose their transactions with the SEC.
Shares of Eleven Biotherapeutics (NASDAQ:EBIO) traded down 2.06% on Tuesday, hitting $11.42. The stock had a trading volume of 2,993 shares. Eleven Biotherapeutics has a 52-week low of $9.502 and a 52-week high of $19.333. The stock has a 50-day moving average of $12.04 and a 200-day moving average of $13.00. The company’s market cap is $175.8 million.
Eleven Biotherapeutics (NASDAQ:EBIO) last issued its quarterly earnings data on Wednesday, August 13th. The company reported ($0.51) earnings per share for the quarter, missing the analysts’ consensus estimate of ($0.47) by $0.04. Analysts expect that Eleven Biotherapeutics will post $-1.84 EPS for the current fiscal year.
Eleven Biotherapeutics, Inc, is a United States-based company, which develops protein-based biotherapeutics.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.